Eagle Genomics ‘delights’ PM with expansion of India office
The advancement of the microbiome as a crucial part of human healthcare will be accelerated following the expansion of Eagle Genomics’ new operation in India, says CEO Anthony Finbow.
The facility is in the innovation hub of Laxmi Cyber City in Hyderabad, the capital of southern India’s Telangana state and a major centre for the technology and biotechnology industries (India’s Genome Valley is close).
The latest milestone will significantly expand the existing team of 20 engineers working on Eagle Genomics’ ground-breaking approach to networking microbiome science – with its e[datascientist]knowledge discovery platform – to help address the world’s grand challenges including a secure and sustainable future for our food, water, soil, health and the planet.
UK prime minister Boris Johnson said: “I’m delighted that Eagle Genomics is expanding into India to make the most of the opportunities for UK businesses in one of the world’s biggest economies.
Mr Finbow said: “Our exporters are brilliant ambassadors for Britain, and I hope today’s announcement is just the start of what you can do for India and the UK.
“The buildout of both the engineering and science teams in Hyderabad has already had a significant impact on Eagle Genomics’ growth.”
“We have been able to hire highly skilled, talented engineers in quantities and at a speed that we would not have been able to achieve had we sought to hire in the UK alone.
“This increased capacity, which will also lead to more hires in the UK to serve the vast Indian opportunity, is already positively impacting the cadence of our platform development, which opens up additional customer verticals and directly leads to growth in terms of customers won and the access to our most proximate addressable markets.”
Deepak Bagla, CEO of Invest India, added: “We are delighted to support Eagle Genomics on its India expansion plans. Eagle Genomics has made the right decision: to expand cutting-edge emerging technology innovation by partnering with India. Collaboration between UK and Indian organisations – with our ability to build world-class innovation and businesses together – is a recipe for truly global competitiveness.”
India’s interest in the microbiome is rising quickly. To date, organisations including the Indian Council of Agricultural Research, The International Crops Research Institute for the Semi-Arid Tropics, the Indian Council of Medical Research, Bangalore Life Science Cluster and the Department of Biotechnology are increasing their research into the role of the microbiome on crop growth, population health, environmental sustainability, and more.
Current Eagle Genomics customers include global corporates such as Unilever and Cargill, “brands which have understood the substantial role of microbes in maintaining health and wellbeing and promoting renewal of the natural environment”.
The company has offices in Paris, New York, London, Potsdam and Kiev as well as Hyderabad and Cambridge.
“We need a solution that is enterprise-class,” says Anthony of the various locations. “We require robust data to do the science, with AI specialisation and bioinformaticians in Europe, and a build team in Hyderabad.
“When it comes to genomics, there is very little variation geographically. But with the microbiome the data varies vastly in different locations –but the diversity in the human gut and in the diversity of the soil is reducing. We need to understand more broadly how the microbiome interacts – with humans and with animals.”
Eagle Genomics continues to operate from the BioData Innovation Centre on the Wellcome Genome Campus as it proceeds with an accelerated phase of discovery for the microbiome.
Currently, the exponential spread of Covid-19 in India continues to cause extreme alarm.
“We are concerned for the local population and for our employees,” said Anthony, who added that a Series B funding round is expected “in the second half of the year”.